Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8548499 | 0.88 | MEN1 (0.36) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL8549281 | 0.87 | KDM4E (0.35) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL8550091 | 0.86 | MEN1 (0.38) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL8548495 | 0.81 | MEN1 (0.35) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL9616425 | 0.78 | — | — | |
| SCHEMBL9737687 | 0.76 | AGTR1 (0.47) | — | |
| SCHEMBL9318424 | 0.76 | AGTR2 (0.38) | — | |
| SCHEMBL7303338 | 0.75 | AR (0.34) | MEN1KMT2ALMNAALDH1A1NPC1 | |
| SCHEMBL8544448 | 0.73 | KMT2A (0.46) | KMT2AALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL8548840 | 0.73 | KDM4E (0.35) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0514198-B1 | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group | GLAXO GROUP LTD (GB) | 1998-08-05 | — | — | EP | disclosed |
| US-5498722-A | HYPOTENSIVES | GLAXO GROUP (GB) | 1996-03-12 | — | — | US | disclosed |
| US-5374646-A | Treatment or prophylasix of hypertension and diseases associated with cognitive disorders | GLAXO GROUP LIMITED (GB) | 1994-12-20 | — | — | US | disclosed |
| US-5332831-A | Angiotensin antagonist | GLAXO GROUP LIMITED (GB) | 1994-07-26 | — | — | US | disclosed |
| US-5317023-A | 2-Phenyl-(imidazo(4,5-b)pyridyl-methyl-) derivatives; hypertensive agents; cognition activators | GLAXO GROUP LIMITED (GB) | 1994-05-31 | — | — | US | disclosed |
| US-5252593-A | Hypotensive agents, cognition activators | GLAXO GROUP LIMITED (GB) | 1993-10-12 | — | — | US | disclosed |
| WO-1992020679-A1 | BENZOFURAN DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020673-A1 | ANTIHYPOTENSIVE BENZOFURAN DERIVATIVES WITH N-LINKED 1H-IMIDAZOLYLMETHYL-5-CARBOXAMIDE SUBSTITUENTS | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | disclosed |
| EP-0514216-A1 | Antihypotensive benzofuran derivatives with N-linked 1H-imidazolyl-methyl-5-carboxamide substituents | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514197-A1 | Anti-hypertensive benzofuran derivatives substituted by N-imidazolyl-methyl groups which are condensed with optionally nitrogen containing, six-membered rings | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| EP-0514198-A1 | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
| EP-0505954-A1 | N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity | GLAXO GROUP LIMITED (GB) | 1992-09-30 | — | — | EP | disclosed |
| EP-0434249-A2 | Benzofuran derivatives | GLAXO GROUP LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |